<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753152</url>
  </required_header>
  <id_info>
    <org_study_id>MT07-CN16NLF701</org_study_id>
    <nct_id>NCT03753152</nct_id>
  </id_info>
  <brief_title>Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial Folds</brief_title>
  <official_title>A Multicenter Randomized, Evaluator-Blinded, Active Controlled Design Study to Evaluate the Safety and Effectiveness of Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical investigation is a randomized, evaluator-blind, active controlled,
      noninferiority study to evaluate the effectiveness and safety of Neuramis® Deep Lidocaine
      when compared with YVOIRE® Volume Plus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Males or females between 18 and 75 years of age, who want to correct both NLFs with 3 or 4
      points in the WSRS and who provided written informed consent are to be included in the
      investigation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WSRS improvement rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>WSRS improvement rate at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of WSRS from Week 4, 12, 24, 36, and 52</measure>
    <time_frame>Week 4, 12, 24, 36, and 52</time_frame>
    <description>Change of WSRS from Week 4, 12, 24, 36, and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WSRS improvement rate on Week 4, 12, 36, and 52</measure>
    <time_frame>Week 4, 12, 36, and 52</time_frame>
    <description>WSRS improvement rate on Week 4, 12, 36, and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAIS improvement rate on Week 4, 12, 24, 36, and 52</measure>
    <time_frame>Week 4, 12, 24, 36, and 52</time_frame>
    <description>GAIS improvement rate on Week 4, 12, 24, 36, and 52</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Investigational medical device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuramis® Deep Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>YVOIRE® Volume Plus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>experimental</intervention_name>
    <description>Neuramis® Deep Lidocaine</description>
    <arm_group_label>Investigational medical device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>comparator</intervention_name>
    <description>YVOIRE® Volume Plus</description>
    <arm_group_label>Comparator device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 to 75 years of age.

          2. Subjects who desire correction of bilateral NLFs that are rated as 3 or 4 points on
             the WSRS.

        Exclusion Criteria:

          1. Subjects who have received anticoagulation, antiplatelet, or thrombolytic medications,
             anti inflammatory medications.

          2. Subjects who had soft tissue augmentation, medium or deep peeling, or dermal
             photorejuvenation on the lower inferior orbital rim for wrinkle correction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinhua XU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HuaShan hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

